Table.
Clinical, Optical Coherence Tomography, and Optical Coherent Tomography Angiography Findings of Central Serous Chorioretinopathy Subgroups and Control Subjects
| Quantitative Analyses in CSC Subgroups | ||||
|---|---|---|---|---|
| RPE-CSC Group | Choroidal-CSC Group | MNV Group | Controls | |
| Group | 1 | 2 | 3 | 4 |
| Number of pts | 35 | 43 | 18 | 210 |
| LogMAR BCVA baseline | 0.23 ± 0.32 | 0.14 ± 0.12 | 0.32 ± 0.18 | 0.0 ± 0.0 |
| LogMAR BCVA 1-year F/U | 0.19 ± 0.23 | 0.08 ± 0.25 | 0.25 ± 0.19 | |
| LogMAR BCVA 2-year F/U | 0.21 ± 0.22 | 0.06 ± 0.16 | 0.31 ± 0.26 | |
| P value (2-Y vs. baseline) | 0.09 | 0.02* | 0.73 | |
| CMT baseline (µm) | 326 ± 139 | 374 ± 123 | 271 ± 66 | 233 ± 19 |
| CMT 1-year F/U (µm) | 245 ± 100 | 264 ± 84 | 228 ± 49 | |
| CMT 2-year F/U (µm) | 235 ± 76 | 253 ± 99 | 242 ± 57 | |
| P value (2-Y vs. baseline) | <0.01* | <0.01* | 0.07 | |
| RT baseline (µm) | 429 ± 91 | 463 ± 108 | 387 ± 94 | 347 ± 17 |
| RT 1-year F/U (µm) | 352 ± 76 | 361 ± 64 | 342 ± 56 | |
| RT 2-year F/U (µm) | 348 ± 61 | 362 ± 111 | 343 ± 86 | |
| P value (2-Y vs. baseline) | <0.01* | <0.01* | 0.07 | |
| CT baseline (µm) | 324 ± 36 | 493 ± 51 | 366 ± 107 | 340 ± 79 |
| CT 1-year F/U (µm) | 325 ± 48 | 473 ± 57 | 354 ± 125 | |
| CT 2-year F/U (µm) | 324 ± 39 | 466 ± 62 | 351 ± 133 | |
| P value (2-Y vs. baseline) | 0.99 | <0.01* | 0.09 | |
| SLT baseline (µm) | 93 ± 33 | 135 ± 25 | 49 ± 12 | 100 ± 21 |
| SLT 1-year F/U (µm) | 95 ± 23 | 127 ± 25 | 51 ± 11 | |
| SLT 2-year F/U (µm) | 88 ± 19 | 125 ± 22 | 42 ± 19 | |
| P value (2-Y vs. baseline) | 0.45 | 0.04* | 0.14 | |
| HLT baseline (µm) | 231 ± 42 | 358 ± 43 | 317 ± 108 | 243 ± 63 |
| HLT 1-year F/U (µm) | 230 ± 47 | 347 ± 50 | 303 ± 125 | |
| HLT 2-year F/U (µm) | 233 ± 33 | 341 ± 56 | 309 ± 129 | |
| P value (2-Y vs. baseline) | 0.41 | 0.04* | 0.31 | |
| P Value | 1 vs. 2 | 1 vs. 3 | 2 vs. 3 | |
| BCVA baseline | 0.63 | 0.14 | 0.007 | |
| BCVA 2-year F/U | 0.681 | <0.01* | <0.01* | |
| CMT baseline (µm) | 0.258 | 0.370 | 0.01* | |
| CMT 2-year F/U (µm) | >0.05 | >0.05 | >0.05 | |
| RT baseline (µm) | 0.407 | 0.448 | 0.023 | |
| RT 2-year F/U (µm) | >0.05 | >0.05 | >0.05 | |
| CT baseline (µm) | <0.01* | 0.641 | <0.01* | |
| CT 2-year F/U (µm) | <0.01* | 0.628 | <0.01* | |
| SLT baseline (µm) | <0.01* | <0.01* | <0.01* | |
| SLT 2-year F/U (µm) | <0.01* | <0.01* | <0.01* | |
| HLT baseline (µm) | <0.01* | <0.01* | 0.06 | |
| HLT 2-year F/U (µm) | <0.01* | <0.01* | 0.333 | |
Legend: Statistically significant values are indicated by (*). The following abbreviations were used: best corrected visual acuity (BCVA), central macular thickness (CMT), retinal thickness (RT), choroidal thickness (CT), Sattler layer thickness (SLT), and Haller layer thickness (HLT).